Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Volume-Staged Stereotactic Radiosurgery in Pediatric Patients With Large Brain Arteriovenous Malformations: An International, Multicenter Study. Neurosurgery 2026 Jun 18

Date

06/16/2026

Pubmed ID

42300133

DOI

10.1227/neu.0000000000004136

Scopus ID

2-s2.0-105047118555 (requires institutional sign-in at Scopus site)

Abstract

BACKGROUND AND OBJECTIVES: Pediatric large-volume brain arteriovenous malformations (AVMs) carry a substantial lifelong hemorrhage risk, neurological symptoms, and treatment morbidity. Single-session stereotactic radiosurgery (SRS) is often unsuitable due to constraints on dose-volume toxicity. Volume-staged SRS (VS-SRS) enables sequential dosing of large nidus volumes, potentially enhancing safety while maintaining efficacy. Evidence in children remains limited. We aimed to evaluate outcomes of VS-SRS for large AVMs in pediatric patients.

METHODS: A multicenter retrospective cohort was assembled from 21 centers, including patients aged younger than 21 years treated with VS-SRS for AVMs >10 cm3. Clinical and radiological end points included obliteration, hemorrhage, and permanent symptomatic radiation-induced changes (RIC).

RESULTS: A total of 103 patients were included (median age 14 years; IQR, 12-17). The median nidus volume at first stage was 18.2 cm3 (IQR, 12.3-25.6). Median prescription dose per stage was 17 Gy (IQR, 16-18). The median clinical follow-up from the first stage was 57.5 months (IQR, 25-138). Obliteration occurred in 42 of 103 patients (40.8%), with actuarial rates of 6.9% (95% CI: 2.8-14) at 3 years and 29% (95% CI: 20-39) at 5 years. Hemorrhage occurred in 17 of 103 patients (16.5%) during follow-up, and permanent RIC was observed in 9 of 103 patients (8.7%).

CONCLUSION: VS-SRS is a reasonably safe, selected option for pediatric large-volume AVMs when microsurgical or endovascular cure is not feasible or prudent. Delivering ≥17 Gy per stage while limiting each treatment volume to <15 cm3 supports durable nidus control with acceptable toxicity. VS-SRS represents a key modality in multidisciplinary management of this historically difficult-to-treat population.

Author List

Hajikarimloo B, Tos SM, Ferguson R, Mantziaris G, Shinya Y, Chan JW, Sneed PK, McDermott MW, Seymour ZA, Grills I, Nabeel AM, Reda WA, Tawadros SR, Abdelkarim K, El-Shehaby AMN, Emad RM, Bin-Alamer O, Lunsford LD, Niranjan A, Peker S, Samanci Y, Lee CC, Yang HC, Sheehan D, Sheehan K, Liscak R, Chytka T, Alzate J, Kondziolka D, Meng Y, Martinez Moreno N, Martinez Álvarez R, Hallan DR, Fritch C, Jareczek FJ, Sciscent BY, Mathieu D, Carrier L, Abdelsalam A, Starke RM, Benjamin C, Almeida T, Pratap Singh S, Tripathi M, Speckter H, Lazo E, Chen CJ, Esquenazi Y, Becerril-Gaitan A, Amsbaugh MJ, Blanco AI, Upadhyay R, Palmer JD, Franzini A, Picozzi P, Alberto Andrea Lanterna L, Bowden GN, Peterson JL, Warnick RE, Chiang VL, Pikis S, Sheehan JP

Author

Francis J. Jareczek PhD, MD Assistant Professor in the Neurosurgery department at Medical College of Wisconsin